Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis

被引：0

作者：

Antoni, C ^{[1
]}

Kalden, JR ^{[1
]}

机构：

[1] Univ Erlangen Nurnberg, Inst Immunol & Rheumatol, Dept Med 3, D-91023 Erlangen, Germany

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 1999年 / 17卷 / 06期

关键词：

infliximab; methotrexate; tumor necrosis factor; combination treatment; rheumatoid arthritis; efficacy; side effects; immunogenecity;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Infliximab, a chimeric anti-TNF alpha antibody, showed in two double-blind placebo-controlled trials efficacy in combination with methotrexate (MTX) inpatients with severe rheumatoid arthritis (RA). Whereas in the first trial low-dose MIX or placebo was compared to infliximab alone and in combination, the second trial compared infliximab to placebo inpatients with active RA despite maximal tolerated MTX treatment. Infliximab showed synergistic effects in combination with MTX. The immunogenicity of infliximab was reduced by the combination. Infliximab in combination with high-dose MTX is effective and safe in long-term treatment up to 54 weeks.

引用

页码：S73 / S77

页数：5

共 50 条

[1] Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
Kavanaugh, A
St Clair, EW
McCune, WJ
Braakman, T
Lipsky, P
JOURNAL OF RHEUMATOLOGY, 2000, 27 (04) : 841 - 850
[2] Combination therapy with the chimeric monoclonal antitumour necrosis factor infliximab (Remicade) plus methotrexate in rheumatoid arthritis patients
Manger, B
Dechant, B
Antoni, C
Kalden, JR
AKTUELLE RHEUMATOLOGIE, 2001, 26 (04) : 159 - 161
[3] Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis
Kavanaugh, AF
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1998, 24 (03) : 593 - +
[4] Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis.
Mugnier, B
Bouvenot, G
REVUE DE MEDECINE INTERNE, 2000, 21 (10): : 854 - 862
[5] Anti-tumor necrosis factor-alpha therapy with the chimeric monoclonal antibody infliximab in severe undifferentiated spondyloarthropathy
Schnarr, S
Huelsemann, JL
Merkesdal, S
Brandt, J
Braun, J
Prudlo-Winkler, S
Zeidler, H
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 422 - 422
[6] Pilot study of chimeric monoclonal anti-tumor necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis
Chaturvedi, VP
ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3421 - 3421
[7] Anti-tumor necrosis factor therapy with infliximab decreases the risk of stroke in patients with rheumatoid arthritis.
Wolfe, F
Nadareishvili, ZG
Hallenbeck, JM
Michaud, K
ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4099 - 4099
[8] Requirement of methotrexate in combination with anti-tumor necrosis factor-α therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis
Matsuno, Hiroaki
Yoshida, Kaoru
Ochiai, Akira
Okamoto, Masahiro
JOURNAL OF RHEUMATOLOGY, 2007, 34 (12) : 2326 - 2333
[9] Treatment of pediatric Crohn's disease (CD) with anti-tumor necrosis factor α chimeric monoclonal antibody (infliximab)
Kugathansan, S
Rivera, MT
Martinez, A
Binion, DG
Werlin, SL
GASTROENTEROLOGY, 1999, 116 (04) : A755 - A755
[10] Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
Paleolog, EM
Hunt, M
Elliott, MJ
Feldmann, M
Maini, RN
Woody, JN
ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1082 - 1091

← 1 2 3 4 5 →